Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Experimental Product 1% Colloidal Oatmeal Balm · 1 trial · 1 indication
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
The severity of the itch was assessed by the subject using a 0-10 cm visual analog scale (VAS) where 0 = no itch and 10 = worst itch imaginable.
| Arm | Type | Description |
|---|---|---|
| Positive Control | ACTIVE_COMPARATOR | Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin. |
| Experimental | EXPERIMENTAL | Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed. |
| Name | Type | Description |
|---|---|---|
| EpiCeram Skin Barrier Emulsion | DEVICE | EpiCeram Skin Barrier Emulsion |
| Experimental Product 1% Colloidal Oatmeal Balm | DRUG | Experimental Product 1% Colloidal Oatmeal Balm |
Inclusion Criteria: 1. Able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) 2. Male or female of any race or ethnicity, ages 12 and older 3. Diagnosed as having eczema 4. Willing to stop use of all non-assigned moisturizers and/or creams for ...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
Experimental Product 1% Colloidal Oatmeal Balm is used for atopic dermatitis, a skin condition characterized by dry, itchy skin. It is being developed as a topical treatment for this dermatological condition.
Experimental Product 1% Colloidal Oatmeal Balm is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker JNJ.
Experimental Product 1% Colloidal Oatmeal Balm is in Phase 2 of clinical development. It is an investigational product and has not yet been approved by regulatory authorities.
Experimental Product 1% Colloidal Oatmeal Balm has one completed clinical trial, NCT02691507, which was a Phase 2 study. The trial enrolled 53 participants in the United States and evaluated the therapeutic benefit of the balm on dry, itchy skin in adults and children with eczema.
Experimental Product 1% Colloidal Oatmeal Balm contains 1% colloidal oatmeal as its active ingredient. Colloidal oatmeal is known for its skin-soothing properties, helping to relieve dryness and itching associated with atopic dermatitis.